Innovation

View All
Bulgaria's Startup Scene is Heating Up With AI, Fintech, and Robots - Professional coverage
BusinessInnovationStartups

Bulgaria’s Startup Scene is Heating Up With AI, Fintech, and Robots

According to EU-Startups, Bulgaria is strengthening its position as a Southeast European tech hub, powered by Sofia's talent pool and…

AI Is Everywhere Now. The Real Edge? Human Judgment. - Professional coverage
AIInnovationSoftware

AI Is Everywhere Now. The Real Edge? Human Judgment.

According to Forbes, the 2025 LinkedIn Workplace Learning Report reveals a striking 91% of learning and development professionals now say…

Strategy Consulting Has a Big, Expensive Problem - Professional coverage
BusinessInnovationSoftware

Strategy Consulting Has a Big, Expensive Problem

According to Fast Company, the fundamental value proposition of traditional strategy consulting is becoming obsolete. The article argues that the…

HealthcareResearchScience

Growth Factor Therapy Shows Extended Heart Repair in Preclinical Study

A groundbreaking study demonstrates extended cardiac function improvement using platelet-derived growth factor-AB following myocardial infarction. The research, conducted in a clinically relevant porcine model, shows therapeutic benefits lasting 60 days post-treatment with comprehensive multi-modality assessment.

Breakthrough in Cardiac Regeneration

Researchers have demonstrated extended improvement in cardiac function using platelet-derived growth factor-AB (PDGF-AB) as a therapeutic agent for heart repair following myocardial infarction, according to a recent study published in npj Regenerative Medicine. The preclinical investigation, conducted in a porcine model that closely mimics human heart conditions, reportedly shows promising results for lasting cardiac recovery.

BiotechnologyHealthcareResearch

Study Reveals Organ-Specific Metabolic Responses to Fenofibrate Treatment in Rats

A comprehensive study examining fenofibrate’s effects reveals striking differences in how liver and kidney tissues respond to the medication. Researchers found significantly stronger metabolic activation in liver tissue compared to kidneys, with implications for understanding drug mechanisms and potential side effects.

Differential Organ Response to Common Medication

New research published in Scientific Reports reveals that fenofibrate, a commonly prescribed lipid-lowering medication, activates metabolic pathways differently in liver and kidney tissues, according to the study findings. The five-day rat exposure study demonstrated that while both organs showed responses to the drug, the liver exhibited significantly stronger activation of lipid metabolism pathways than the kidney.